These patients had trends toward higher frequencies of diffuse cutaneous SSc (dcSSc) and anti-topoisomerase I (topo I) antibodies and had lower FVC and DLCO and higher baseline KL-6 levels than the entire SSc population. The gene discussed is MUC1; the disease is systemic sclerosis.